Brigatinib

Generic Name
Brigatinib
Brand Names
Alunbrig
Drug Type
Small Molecule
Chemical Formula
C29H39ClN7O2P
CAS Number
1197953-54-0
Unique Ingredient Identifier
HYW8DB273J
Background

Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal ...

Indication

The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related...

Associated Conditions
Metastatic Non-Small Cell Lung Cancer
Associated Therapies
-
Clinical Trials
Related News

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Phase 2
Terminated
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: brigatinib
First Posted Date
2016-03-11
Last Posted Date
2023-01-26
Lead Sponsor
Criterium, Inc.
Target Recruit Count
32
Registration Number
NCT02706626
Locations
🇺🇸

Duke University, Durham, North Carolina, United States

🇺🇸

Vanderbilt Unversity Medical Center, Nashville, Tennessee, United States

🇺🇸

University of Texas, Southwestern, Dallas, Texas, United States

and more 1 locations

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Brigatinib
First Posted Date
2014-03-24
Last Posted Date
2021-03-15
Lead Sponsor
Ariad Pharmaceuticals
Target Recruit Count
222
Registration Number
NCT02094573

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

First Posted Date
2011-10-10
Last Posted Date
2021-08-17
Lead Sponsor
Ariad Pharmaceuticals
Target Recruit Count
137
Registration Number
NCT01449461
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy